Secretory leukocyte protease inhibitor (SLPI) in mucosal fluids inhibits HIV-1

Oral Diseases

Volumn 3, Issue SUPPL. 1, 1997, Pages

  Wahl, S M ^a   McNeely, T B ^a   Janoff, E N ^b   Shugars, D ^c   Worley, P ^d   Tucker, C ^a   Orenstein, J M ^d  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

HIV 1; Macrophages; SLPI

Indexed keywords

SALIVA PROTEIN; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR;

ANTIVIRAL ACTIVITY; BREAST FEEDING; BREAST MILK; CONFERENCE PAPER; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; PROTEIN PURIFICATION; SALIVA ANALYSIS; VIRUS TRANSMISSION;

EID: 0030914690     PISSN: 1354523X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1601-0825.1997.tb00377.x     Document Type: Conference Paper

References (49)

1. Abbinante-Nissen JM, Simpson LG, Leikauf GD (1993). Neutrophil elastase increases secretory leukocyte protease inhibitor transcript levels in airway epithelial cells. Am J Physiol 265 (Lung Cell Mol Physiol 9): L286-L292.
2. Abbinante-Nissen JM, Simpson LG, Leikauf GD (1995). Corticosteroids increase secretory leukocyte protease inhibitor transcript levels in airway epithelial cells. Am J Physiol 268 (Lung Cell Mol Physiol 12): L601-L606.
3. Abe T, Kobayashi N, Yoshimura K et al (1991). Expression of the secretory leukoprotease inhibitor gene in epithelial cells. J Clin Invest 87: 2207-2215.
4. Barr CE, Miller LK, Lopez MR et al (1992). Recovery of infectious HIV-1 from whole saliva. J Am Dent Assoc 123: 36-48
5. Bergey EJ, Cho MI, Blumberg BM et al (1994). Interaction of HIV-1 and human salivary mucins. J Acquir Immune Deficiency 7: 995-1002.
6. Cann AJ, Zack JA, Go S et al (1990). Human Immunodeficiency Virus type 1 T-cell tropism is determined by events prior to provirus formation. J Virol 64: 4735-4742.
7. Eisenberg SP, Hale KK, Heimdal P et al (1990). Location of the protease-inhibitory region of secretory leukocyte protease inhibitor. J Biol Chem 265: 7976-7981.
8. Feng Y, Broder C, Kennedy P et al (1996). HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272: 872-876.
9. Finberg RW, Wahl SM, Allen JB et al (1991). Selective elimination of HIV-1 infected cells with an interleukin-2 receptor-specific cytotoxin. Science 252: 1703-1705.
10. Fox PC, Wolff A, Yeh C-K et al (1988). Saliva inhibits HIV-1 infectivity. J Am Dent Assoc 116: 635-637.
11. Franken C, Meijer CJL, Dijkman (1989). Tissue distribution of antileukoprotease and lysozyme in humans. J Histochem Cytochem 37: 493-498.
12. Freidland GH, Saltzman R, Rogers MF et al (1996). Lack of household transmission of HTLV-III infection. N Engl J Med 314: 344-349.
13. Fritz H (1988). Human mucus proteinase inhibitor (Human MPI). Human seminal inhibitor I (HUSH-I), antileucoprotease (ALP). Secretory leukocyte protease inhibitor (SLPI). Biol Chem 369: 79-82.
14. Fryksmark U, Prellner T, Tegner H et al (1984). Studies on the role of antileukoprotease in respiratory tract diseases. Eur J Respir Dis 65: 201-209.
15. Gerberding JL, Bryant-Leblanc CE, Nelson K et al (1987). Risk of transmitting the human immunodeficiency virus, cytomegalovirus, and hepatitis B virus to health care workers exposed to patients with AIDS and AIDS-rleated conditions. J Infect Dis 156: 1-8.
16. Goto Y, Yeh C-K, Notkins AL et al (1991). Detection of proviral sequences in saliva of patients infected with human immunodeficiency virus type I. AIDS Res Human Retrovir 7: 343-347.
17. Greenspan JS, Greenspan D (1992). Oral lesions associated with HIV infection. In: Wormer Gary P. ed. AIDS and other manifestations of HIV infection. 2nd ed. Raven Press Ltd: New York, pp 489-498.
18. Groopman JE, Salahuddin SZ, Sarngadharan MG et al (1984). HTLV III in saliva of people with AIDS-related complex healthy homosexual men at risk for AIDS. Science 226: 447-449.
19. Grutter MG, Fendrich G, Huber R et al (1988). The 2.5 A X-ray crystal structure of the acid-stable proteinase inhibitor from human mucous secretions analysed in its complex with bovine α-chymotrypsin. EMBO J 7: 345.
20. Hiemstra PS, Maassen RJ, Stolk J et al (1996). Antimicrobial activity of antileukoprotease. Infection and Immunity (in press).
21. Ho DD. Byington RE, Schooley RT et al (1985). Infrequency of isolation of HTLV-III virus from saliva in AIDS. New Eng J Med 313: 1606.
22. Janoff EN, Eidman K, McNeely T et al (1996). Secretory Leukocyte Protease Inhibitor (SLPI): An HIV-1 Inhibitory Protein in Mucosal Fluids. Submitted.
23. Klein RS, Phelan JA, Freeman PH et al (1988). Low occupational risk of human immunodeficiency virus infection among dental professionals. N Engl J Med 318: 86-90.
24. Kramps JA, Franken C, Dijkman JH (1984). ELISA for quantitative measurement of low-molecular-weight bronchial protease inhibitor in sputum. Am Rev Respir Dis 129: 959-963.
25. Kramps JA, Franken C, Meijer CJLM et al (1981). Localization of low molecular weight protease inhibitor in serous secretory cells of the respiratory tract. J Histochem Cytochem 29: 712-719.
26. Levy JA, Greenspan D (1988). HIV in saliva. Lancet 2: 1248.
27. Malamud D, Freidman HM (1993). HIV in the oral cavity: Virus, viral inhibitory activity, and antiviral antibodies: A review. Crit Rev Oral Biol Med 4: 461-466.
28. Maruyama M, Hay JG, Yoshimura K et al (1994). Modulation of secretory leukoprotease inhibitor gene expression in human bronchial epithelial cells by phorbol ester. J Clin Invest 94: 368-75.
29. McNeely TB, Dealy M, Dripps DJ et al (1995). Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-HIV-1 activity in vitro. J Clin Invest 96: 456-464.
30. McNeely TB, Shugars DC, Rosendahl M et al (1996). Secretory leukocyte protease inhibitor binds to monocytes and inhibits HIV-1 infecton by disrupting an initial step of the viral cycle prior to reverse transcription. Submitted.
31. Miller KW, Evans RJ, Eisenberg SP et al (1989). Secretory leukocyte protease inhibitor binding to mRNA and DNA as a possible cause of toxicity to Escherichia coli. J Bacteriol 171: 2166-2172.
32. Moore BE, Flaitz CM, Coppenhaver DH et al (1993). HIV recovery from saliva before and after dental treatment: Inhibitors may have critical role in viral inactivation. J Am Dent Assoc 124: 67-74.
33. Ohlsson M, Fryksmark U, Polling A et al (1984). Localization of antileukoprotease in the parotid and the submandibular salivary glands. Acta Otolaryngol 98: 47-151.
34. Qureshi MN, Barr CE, Seshamma T et al (1995). Infection of oral mucosal cells by human immunodeficiency virus type I in seronegative persons. J Infect Dis 171: 190-193.
35. Rudolphus A, Stolk J, van Twisk C et al (1992). Detection of extracellular neutrophil elastase in hamster lungs after intratracheal instillation of E. coli lipopolysaccharide using a fluorogenic, elastase-specific, synthetic substrate. Am J Path 141: 153-160.
36. Sallenave JM, Shulmann J, Crossley J et al (1994). Regulation of secretory leukocyte proteinase inhibitor (SLPI) and elastase-specific inhibitor (ESI/elafin) in human airway epithelial cells by cytokines and neutrophilic enzymes. Am J Respir Cell Mol Biol 11: 733-741.
37. Schiodt M, Greenspan D, Levy JA et al (1989). What is the role of HIV in HIV-associated salivary gland disease? AIDS 3: 819-820.
38. Schupfer PC, Murph JR, Bale JF (1986) Survival of cytomegalovirus in paper diapers and saliva. Pediair Infect Dis 5: 677-679.
39. Shugars DC, McNeely TB, Eisenberg SP et al (1996). Secretory leukocyte protease inhibitor targets an early event in HIV infection. J Dent Res 75: 114.
40. Stromatt SC (1993). Secretory leukocyte protease inhibitor in cystic fibrosis. Agents Actions Suppl 42: 103-110.
41. Thompson RC, Ohlsson K (1986). Isolation, properties, and complete amino acid squences of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase. Proc Natl Acad Sci USA 83: 6692-9996.
42. Van de Perre P, Simonon A, Msellati P et al (1991). Postnatal transmission of human immunodeficiency virus type 1 from mother to infant. New Engl J Med 325: 593-598.
43. Wahl SM, Allen JB, Gartner S et al (1989). HIV-1 and its envelope glycoprotein down-regulate chemotactic ligand receptors and chemotactic function of peripheral blood monocytes. J Immunol 142: 3555-3559.
44. Wahl SM, McNeely TB, Eisenberg SP (1995). A SLPI defense against HIV. The NIH Catalyst 3: 8-22.
45. Wahl SM, Orenstein JM, Smith PD (1996). Macrophage function in HIV infection. In: S. Gupta, ed. Immunology of HIV Infection. Plenum Press, NY, pp 303-336.
46. Wahl SM, Worley P, Jin WW et al (1997). Anatomic dissociation between HIV-1 and its endogenous inhibitor in mucosal tissues. Am J Pathol (in press).
47. Wild CT, Shugars DC, Greenwell TK et al (1994). Peptides corresponding to a predictive alpha-helical domain of Human Immunodeficiency Virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci, USA 91: 9770-9774.
48. Yeung SCH, Kazazi F, Randle CGM et al (1993). Patients infected with human immunodeficiency virus type I have low levels of virus in saliva even in the presence of periodontal disease. J Infect Dis 167: 803-809.
49. Ying QL, Kemme M, Simon SR (1994). Functions of the N-terminal domain of secretory leukoprotease inhibitor. Biochemistry 33: 5445-5450.